NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|December 15, 2023

Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04

Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS

A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.

Episodes in this series

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 1 Overview of Non–Small Cell Lung Cancer

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 2 The Role of Biomarkers in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 3 NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 4 The Role of TROP2 as a Biomarker in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 5 NSCLC: Preclinical Studies on TROP2 Expression

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 6 Lung Cancer Treatment: Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 7 Clinical Trial Data on Sacituzumab Govitecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 8 EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 9 Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 10 Antibody-Drug Conjugate Safety Profiles in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 11 Recent Data on Datopotamab Deruxtecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 12 NSCLC: Dato-DXd Combination Therapy

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 13 NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 14 Progress and Unmet Needs in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 15 Future Targeted Therapy Approaches in NSCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

BySabrina Serani

January 30th 2026

Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC

BySabrina Serani

January 17th 2026

Nogapendekin Alfa Inbakicept Shows Promise in Checkpoint-Refractory NSCLC

BySabrina Serani

January 14th 2026

FDA Grants Orphan Drug Designation for Gotistobart in Squamous NSCLC

BySabrina Serani

January 13th 2026

Phase 3 TROPION-Lung17 Trial Initiates TROP2-Directed Therapy in NSCLC

BySabrina Serani

January 13th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

The Targeted Pulse: New Standards in Myeloma, Melanoma, and More

Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC

Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers

BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer